Bristol Myers Squibb selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to cover drug product and finished goods manufacturing from late development through launch. The site choice supports BMS’s broader strategy of scaling production pipelines and reducing bottlenecks across modalities. In parallel, Recursion and Roche, including Genentech, announced plans to co-develop a neuroscience discovery program built on the first validated target discovered through an AI map. The combination pairs BMS-scale manufacturing ambitions with platform-driven discovery collaboration. Taken together, the announcements show BMS and its partners aligning clinical programs with both capacity expansion and discovery tooling investments.